HM2017-39 Phase III Randomized Study of Crenolanib versus Midostaurin Administered FollowingInduction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 MutatedAcute Myeloid Leukemia

Project: Research project

Project Details

Description

HM2017-39 Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
StatusActive
Effective start/end date12/1/1711/30/22

Funding

  • AROG PHARMACEUTICALS, INC

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.